JAMA Network
About The Study: In 2023, reported breast and colorectal cancer screening rebounded from COVID-19 pandemic–related declines and surpassed pre-pandemic estimates. These findings are encouraging given larger-than-expected declines in early-stage breast and colorectal cancer diagnoses in 2020 and increases in distant-stage breast cancer diagnoses through 2021. Cervical cancer screening rates remained below pre-pandemic levels, a troubling trend as early-stage diagnoses continued to decrease in 2021. The persistent decline may in part reflect longer-term declines in patient knowledge and clinician recommendation of cervical cancer screening.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
